4 results match your criteria: "Montreal General Hospital - Room L7-313[Affiliation]"
Medical treatment for botulism.
Cochrane Database Syst Rev
April 2019
Department of Neurology & Neurosurgery, McGill University, Montreal General Hospital - Room L7-313, 1650 Cedar Avenue, Montreal, QC, Canada, H3G 1A4.
Background: Botulism is an acute paralytic illness caused by a neurotoxin produced by Clostridium botulinum. Supportive care, including intensive care, is key, but the role of other medical treatments is unclear. This is an update of a review first published in 2011.
View Article and Find Full Text PDFTreatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.
Cochrane Database Syst Rev
January 2017
Department of Neurology & Neurosurgery, McGill University, Montreal General Hospital - Room L7-313, 1650 Cedar Avenue, Montreal, QC, Canada, H3G 1A4.
Background: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a chronic progressive or relapsing and remitting disease that usually causes weakness and sensory loss. The symptoms are due to autoimmune inflammation of peripheral nerves. CIPD affects about 2 to 3 per 100,000 of the population.
View Article and Find Full Text PDFMedical treatment for botulism.
Cochrane Database Syst Rev
February 2014
Departments of Medicine and Neurology & Neurosurgery, McGill University, Montreal General Hospital - Room L7-313, 1650 Cedar Avenue, Montreal, Quebec, Canada, H3G 1A4.
Background: Botulism is an acute paralytic illness caused by a neurotoxin produced by Clostridium botulinum. Supportive care, including intensive care, is key but the role of other medical treatments is unclear. This is an update of a review first published in 2011.
View Article and Find Full Text PDFMedical treatment for botulism.
Cochrane Database Syst Rev
March 2011
Medicine and Neurology & Neurosurgery, McGill University, Montreal General Hospital - Room L7-313, 1650 Cedar Avenue, Montreal, Quebec, Canada, H3G 1A4.
Background: Botulism is an acute paralytic illness caused by a neurotoxin produced by Clostridium botulinum. Supportive care, including intensive care, is key but the role of other medical treatments is unclear.
Objectives: To assess the effects of medical treatments on mortality, duration of hospitalization, mechanical ventilation, tube or parenteral feeding and risk of adverse events in botulism.